Vanda Pharmaceuticals Inc.
NASDAQ:VNDABiotechnology
-$0.20 today
- Market cap
- $226.76M
- Beta
- 0.60
- P/E (TTM)
- -1.4
- EPS (TTM)
- -$4.03
Volume 0.95M
Average 1.29M
VNDA Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Vanda Pharmaceuticals Inc.NASDAQ: VNDA
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation declines year over year
Q1 FY2026 stock-based compensation of $2.56M fell 13.7% year over year, ahead of the -23.3% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 12.2% from the prior quarter. Over 3 fiscal years it compounded at -16.5% a year.
Context
- Stock-based compensation amounted to 4.4% of revenue in FY2025, down 1.9 pp from a year earlier.
- Stock-based compensation increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -13.7% holds above the trailing-twelve-month pace of -23.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 9.47M USD
- Year-over-year change
- -23.8%
- 4-year CAGR
- -11.4%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 9.47M | -23.8% |
| FY2024 | 2024-12-31 | 12.43M | -11.5% |
| FY2023 | 2023-12-31 | 14.04M | -13.8% |
| FY2022 | 2022-12-31 | 16.28M | +5.9% |
| FY2021 | 2021-12-31 | 15.37M | — |
Stock-Based Compensation vs competitors
How VNDA compares with its peers on the latest reported figures
- VNDA's LTM Mar 2026 stock-based compensation of $9.07M is the 8th largest of the 11 companies compared; the peer median is $15.55M.
- Its year-over-year change of -23.3% is the 7th highest of 11, against a peer median of -7.7%.
- Stock-based compensation amounts to 4.2% of revenue for VNDA, versus a peer median of 193.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $3.98B | +32410.1% | +56.9% | — | |
| LTM Mar 2026 | $33.74M | -35.1% | -23.4% | — | |
| LTM Mar 2026 | $23.07M | -33.2% | -6.0% | 50.9% | |
| LTM Mar 2026 | $19.27M | -0.0% | +25.6% | 335.8% | |
| LTM Mar 2026 | $17.5M | -62.1% | -23.7% | — | |
| LTM Mar 2026 | $13.6M | -8.6% | +16.5% | 37.3% | |
| LTM Mar 2026 | $10.44M | +45.6% | +16.4% | 517.7% | |
| LTM Mar 2026 | $9.07M | -23.3% | -16.5% | 4.2% | |
SGMTSagimet Biosciences Inc. | LTM Mar 2026 | $6.82M | +13.6% | +50.8% | — |
| LTM Mar 2026 | $5.84M | -6.8% | +38.9% | — | |
| LTM Mar 2026 | $1.52M | -69.5% | — | — | |
| Peer median (excluding VNDA) | $15.55M | -7.7% | +16.5% | 193.3% | |
Competitors are the stored peer set for VNDA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 33.15M | 6.28M | 2.51M | (18.9M) | (220.47M) |
| Depreciation & Amortization | 2.84M | 2.73M | 3.01M | 8.13M | (950K) |
| Deferred Income Tax | 6.75M | 1.13M | (1.29M) | (6.48M) | 81.44M |
| Stock-Based Compensation | 15.37M | 16.28M | 14.04M | 12.43M | 9.47M |
| Change in Working Capital | 2.74M | 6.07M | (747K) | (6.56M) | 8.31M |
| Accounts Receivables | (2.47M) | (1.09M) | (707K) | (13.01M) | (7.46M) |
| Inventory | (2.23M) | (4.48M) | (771K) | (29K) | (3.47M) |
| Accounts Payables | 3.04M | 11.79M | (10.98M) | 1.71M | 15.82M |
| Other Working Capital | 4.4M | (151K) | 11.72M | 4.78M | 3.42M |
| Other Non-Cash Items | 3.37M | (507K) | (4.73M) | (4.38M) | 12.76M |
| Operating Cash Flow | 64.21M | 31.98M | 12.8M | (15.76M) | (109.44M) |
| Capital Expenditures | (552K) | (679K) | (383K) | (490K) | (998K) |
| Acquisitions (Net) | 0 | 0 | (100.67M) | (4.23M) | 0 |
| Purchases of Investments | (420.46M) | (349.26M) | (512.61M) | (364.77M) | (112.38M) |
| Sales of Investments | 344.32M | 399.86M | 601.6M | 352.06M | 208.24M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (76.7M) | 49.93M | (12.06M) | (17.43M) | 94.86M |
| Debt Repayment | 0 | 0 | 0 | (155K) | (1.99M) |
| Common Stock Issued | 3.55M | 734K | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 0 | (915K) |
| Financing Cash Flow | 3.55M | 734K | 0 | (155K) | (2.91M) |
| Effect of Forex Changes | (85K) | 315K | 47K | (163K) | 126K |
| Net Change in Cash | (9.02M) | 82.96M | 792K | (33.51M) | (17.36M) |
| Free Cash Flow | 63.66M | 31.31M | 12.42M | (16.25M) | (110.44M) |
Vanda Pharmaceuticals Inc.
NASDAQ:VNDA
Intrinsic Alpha fair value
Locked
Current Price
$3.75
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.